Literature DB >> 22141571

Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart.

Yuquan Xie1, Ruizhen Chen, Xian Zhang, Yong Yu, Yingzhen Yang, Yunzeng Zou, Junbo Ge, Haozhu Chen, Alfredo Garzino-Demo.   

Abstract

The Th17/interleukin (IL)-17 axis controls inflammation and might be important in the pathogenesis of experimental autoimmune myocarditis (EAM) and other autoimmune diseases. However, the mechanism underlying the increased Th17 cell response in coxsackievirus-induced myocarditis remains unclear. This study aimed to elucidate the regulatory mechanisms affected by blocking IL-17A responses in acute virus-induced myocarditis (AVMC) mice. The results showed that IL-17A and COX-2 proteins were significantly increased in the cardiac tissue of acute myocarditis, as were Th17 cells in the spleen. Using anti-mouse IL-17Ab to block IL-17A on day 7 of the viral myocarditis led to decreased expressions of cardiac tumor-necrosis factor alpha, IL-17A and transforming growth factor beta in AVMC mice compared to isotype control mice. COX-2 and prostaglandin E2 proteins were dramatically elevated, followed by marked reductions in CVB3 replication and myocardial injury. These results hint that the Th17/IL-17 axis is intimately associated with viral replication in acute myocarditis via induction of COX-2 and prostaglandin E2.
© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22141571     DOI: 10.1111/j.1574-695X.2011.00918.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  9 in total

Review 1.  Update on coxsackievirus B3 myocarditis.

Authors:  DeLisa Fairweather; Katelyn A Stafford; Yoon K Sung
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

2.  Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance.

Authors:  Haibin Jin; Xiaoming Guo
Journal:  Virol J       Date:  2016-10-10       Impact factor: 4.099

3.  Common variants in IL-17A/IL-17RA axis contribute to predisposition to and progression of congestive heart failure.

Authors:  Chaugai Sandip; Lun Tan; Jin Huang; Qing Li; Li Ni; Katherine Cianflone; Dao Wen Wang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 4.  Prostaglandin E2 As a Modulator of Viral Infections.

Authors:  Willem J Sander; Hester G O'Neill; Carolina H Pohl
Journal:  Front Physiol       Date:  2017-02-14       Impact factor: 4.566

5.  Immunomodulatory Effects of Rhinovirus and Enterovirus Infections During the First Year of Life.

Authors:  Terhi Ruohtula; Anita Kondrashova; Jussi Lehtonen; Sami Oikarinen; Anu-Maaria Hämäläinen; Onni Niemelä; Aleksandr Peet; Vallo Tillmann; Janne K Nieminen; Jorma Ilonen; Mikael Knip; Outi Vaarala; Heikki Hyöty
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

6.  Dissecting the cellular landscape and transcriptome network in viral myocarditis by single-cell RNA sequencing.

Authors:  Ninaad Lasrado; Nicholas Borcherding; Rajkumar Arumugam; Timothy K Starr; Jay Reddy
Journal:  iScience       Date:  2022-02-02

7.  Neutralization of interleukin-38 exacerbates coxsackievirus B3-induced acute myocarditis in mice.

Authors:  Yimin Xue; Mingguang Chen; Qian Chen; Tingfeng Huang; Qiaolian Fan; Fenghui Lin; Jun Ke; Feng Chen
Journal:  Virol J       Date:  2021-11-14       Impact factor: 4.099

8.  Ethyl pyruvate attenuated coxsackievirus B3-induced acute viral myocarditis by suppression of HMGB1/RAGE/NF-ΚB pathway.

Authors:  Ying Yu; Yong Yu; Ming Liu; Peng Yu; Guijian Liu; Yuxi Liu; Yangang Su; Hong Jiang; Ruizhen Chen
Journal:  Springerplus       Date:  2016-02-29

9.  Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.

Authors:  Tomas Raul Wiche Salinas; Boyang Zheng; Jean-Pierre Routy; Petronela Ancuta
Journal:  Respirology       Date:  2020-06-17       Impact factor: 6.175

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.